Interferon Beta-1B
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Interferon Beta-1b: From Multiple Sclerosis to Hairy Cell Leukemia
One-Sentence Summary
Interferon beta-1b (marketed elsewhere as Betaferon®/Betaseron®) is a recombinant type I interferon approved for the treatment of relapsing forms of multiple sclerosis. The TxGNN model predicts it may also be effective for Hairy Cell Leukemia, with 0 registered clinical trials but 4 historical publications (1987–1990) supporting early exploratory activity in this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple Sclerosis (inferred from literature/known use; not confirmed by German regulatory data — data gap) |
| Predicted New Indication | Hairy Cell Leukemia |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L3 |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for interferon beta-1b is not available in this evidence pack. Based on known pharmacology, interferon beta-1b is a recombinant, cysteine-to-serine-substituted type I interferon with potent antiproliferative and immunomodulatory activity, approved for relapsing forms of multiple sclerosis (an autoimmune demyelinating disease of the CNS — see the second predicted indication in this dataset, which the model itself flags as the drug's original approved use rather than a new one).
Type I interferons as a class (including interferon alfa) have long served as an effective, guideline-supported therapy for hairy cell leukemia, a rare B-cell lymphoproliferative disorder that is highly sensitive to interferon-mediated antiproliferative and differentiation-inducing signaling. Because interferon beta-1b binds the same type I interferon receptor and activates overlapping downstream signaling pathways as interferon alfa, it is mechanistically plausible that it could exert similar antileukemic activity — a hypothesis that was in fact tested prospectively in the late 1980s.
However, development of interferon beta-1b in hairy cell leukemia was not pursued further: interferon alfa became the interferon of choice, and purine analogs (cladribine, pentostatin) subsequently displaced interferons altogether as first-line therapy. No modern clinical trials have evaluated interferon beta-1b in this indication since ~1990, so the mechanistic rationale, while sound, rests on dated and small-scale clinical experience rather than contemporary validation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3312839 | 1987 | Cohort | Leukemia | UCLA experience: 51 patients across type I interferons; ~71% hematologic improvement in initial beta-serine-interferon cohort |
| 2736487 | 1989 | Cohort | Cancer | 10 patients treated with rIFN-beta ser (90×10⁶ U SC TIW); 63% normalized peripheral counts, 25% partial hematologic improvement |
| 2082943 | 1990 | Cohort | American Journal of Hematology | 12 patients (10 previously treated) given IV beta-ser interferon 90×10⁶ U TIW; bone marrow involvement 90–100% hairy cells at baseline |
| 2198792 | 1990 | Case Report | American Journal of Clinical Oncology | Patient who failed beta-ser-interferon subsequently achieved complete response with 2'-deoxycoformycin (pentostatin) |
Germany Market Information
No German market authorization records are available for interferon beta-1b in this dataset — the drug's market status is recorded as Not Marketed with 0 licenses.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for hairy cell leukemia is limited to four small, older (1987–1990) cohort/case-report studies (evidence level L3) with no registered modern clinical trials, and the drug currently has no market authorization in Germany. The mechanistic rationale (shared type I interferon receptor pathway with interferon alfa, a historically effective HCL therapy) is plausible but has not been re-tested against current standard-of-care agents (cladribine, pentostatin).
To proceed, the following is needed:
- TFDA/BfArM label data — key warnings and contraindications (currently blocking, DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- A modern comparative or translational study of interferon beta-1b against current HCL standard-of-care (purine analogs) to justify renewed clinical interest
- Clarification of original indication/regulatory status, since
original_indicationsand German license records are both empty in this datasetDisclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.